Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. (Q51607504)

8 April 2018

title

Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. (English)

1 reference

8 April 2018

1 reference

Sanja Dacic

1

1 reference

8 April 2018

Yongli Shuai

2

1 reference

8 April 2018

Samuel Yousem

3

1 reference

8 April 2018

Paul Ohori

4

1 reference

8 April 2018

Marina Nikiforova

5

1 reference

8 April 2018

publication date

23 October 2009

1 reference

8 April 2018

published in

Modern Pathology

1 reference

8 April 2018

volume

23

1 reference

8 April 2018

issue

2

1 reference

8 April 2018

page(s)

159-168

1 reference

8 April 2018

https://scigraph.springernature.com/pub.10.1038/modpathol.2009.154

exact match

0 references

cites work

Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Epidermal growth factor receptor (EGFR) gene copy number detection in non-small-cell lung cancer; a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

EGFR mutation is specific for terminal respiratory unit type adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

EGFR mutations are more frequent in well-differentiated than in poor-differentiated lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid Structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Tumor-infiltrating T lymphocytes: friends or foes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

7 January 2021

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

7 January 2021

Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

7 January 2021

Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

7 January 2021

Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

7 January 2021

Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

7 January 2021

Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

7 January 2021

Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

7 January 2021

CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

7 January 2021

Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2009.154

7 January 2021

10.1038/MODPATHOL.2009.154

Identifiers

DOI

1 reference

8 April 2018

PubMed ID

19855375

1 reference

8 April 2018